The case for renal artery stenting for treatment of renal artery stenosis

Circulation

Volumn 115, Issue 2, 2007, Pages 263-269

  Cooper, Christopher J ^a   Murphy, Timothy P ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN I; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAS PROTEIN; RENIN;

ACUTE HEART INFARCTION; ADRENAL CORTEX; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVASCULARIZATION; STENT; SURGICAL TECHNIQUE; PATHOLOGY; RENAL ARTERY; RENOVASCULAR HYPERTENSION; REVIEW;

HUMANS; HYPERTENSION, RENAL; RENAL ARTERY; RENAL ARTERY OBSTRUCTION; STENTS;

EID: 33846206376     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.619015     Document Type: Article

References (106)

1. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347-379. Abstract.
2. Van Velzer DA, Burge CH, Morris GC Jr. Arteriosclerotic narrowing of renal arteries associated with hypertension. Am J Roentgenol Radium Ther Nucl Med. 1961;86:807-818.
3. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994;90:2056-2069.
4. Meyrier A. Vascular mechanisms of renal fibrosis: vasculonephropathies and arterial hypertension. Bull Acad Natl Med. 1999;183:33-45.
5. Vensel LA, Devereux RB, Pickering TG, Herrold EM, Borer JS, Laragh JH. Cardiac structure and function in renovascular hypertension produced by unilateral and bilateral renal artery stenosis. Am J Cardiol. 1986;58:575-582.
6. Korner PI. Cardiovascular hypertrophy and hypertension: causes and consequences. Blood Press. 1995;2:6-16.
7. Martin LG, Cork RD, Wells JO. Renal vein renin analysis: limitations of its use in predicting benefit from percutaneous angioplasty. Cardiovasc Intervent Radiol. 1993;16:76-80.
8. Schreij G, van Es PN, Schiffers PM, Lavrijssen AT, de Leeuw PW. "Captopril test," with blood pressure and peripheral renin as response variables in hypertensive patients with suspected renal artery stenosis. J Hum Hypertens. 1995;9:741-746.
9. Liard JF, Cowley AW Jr, McCaa RE, McCaa CS, Guyton AC. Renin, aldosterone, body fluid volumes, and the baroreceptor reflex in the development and reversal of Goldblatt hypertension in conscious dogs. Circ Res. 1974;34:549-560.
10. Ayers CR. Renin-angiotensin-aldosterone system in hypertension: the clinical usefulness of measuring components of this system. Va Med Mon (1918). 1969;96:312-314.
11. Bianchi G, Campolo L, Vegeto A, Pietra V, Piazza U. The value of plasma renin concentration per se, and in relation to plasma and extracellular fluid volume in diagnosis and prognosis of human renovascular hypertension. Clin Sci. 1970;39:559-576.
12. Anderson WP, Korner PI, Angus JA, Johnston CI. Contribution of stenosis resistance to the rise in total peripheral resistance during experimental renal hypertension in conscious dogs. Clin Sci (Lond). 1981;61:663-670.
13. Schoenberg SO, Bock M, Kallinowski F, Just A. Correlation of hemodynamic impact and morphologic degree of renal artery stenosis in a canine model. J Am Soc Nephrol. 2000;11:2190-2198.
14. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G, Friberg P. Increased sympathetic nerve activity in renovascular hypertension. Circulation. 1999;99:2537-2542.
15. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057-1062.
16. Mathias CJ, Kooner JS, Peart S. Neurogenic components of hypertension in human renal artery stenosis. Clin Exp Hypertens A. 1987;9:293-306.
17. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346:1954-1962.
18. Pizzolo F, Pavan C, Guarini P, Trabetti E, Girelli D, Corrocher R, Olivieri O. Primary hyperaldosteronism: a frequent cause of residual hypertension after successful endovascular treatment of renal artery disease. J Hypertens. 2005;23:2041-2047.
19. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int. 1997;51:722-727.
20. Converse RL Jr, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, Fouad-Tarazi F, Victor RG. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest. 1992;90:1657-1665.
21. Chabova V, Schirger A, Stanson AW, McKusick MA, Textor SC. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc. 2000;75:437-444.
22. Wollenweber J, Sheps SG, Davis GD. Clinical course of atherosclerotic renovascular disease. Am J Cardiol. 1968;21:60-71.
23. La Batide-Alanore A, Azizi M, Froissart M, Raynaud A, Plouin PF. Split renal function outcome after renal angioplasty in patients with unilateral renal artery stenosis. J Am Soc Nephrol. 2001;12:1235-1241.
24. Watson PS, Hadjipetrou P, Cox SV, Piemonte TC, Eisenhauer AC. Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. Circulation. 2000;102:1671-1677.
25. Harden PN, MacLeod MJ, Rodger RS, Baxter GM, Connell JM, Dominiczak AF, Junor BJ, Briggs JD, Moss JG. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet. 1997;349:1133-1136.
26. Dean RH, Kieffer RW, Smith BM, Oates JA, Nadeau JH, Hollifield JW, DuPont WD. Renovascular hypertension: anatomic and renal function changes during drug therapy. Arch Surg. 1981;116:1408-1415.
27. Meaney TF, Dustan HP, McCormack LJ. Natural history of renal arterial disease. Radiology. 1968;91:881-887.
28. Tollefson DF, Ernst CB. Natural history of atherosclerotic renal artery stenosis associated with aortic disease. J Vasc Surg. 1991;14:327-331.
29. Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am. 1984;11:383-392.
30. Guzman RP, Zierler RE, Isaacson JA, Bergelin RO, Strandness DE Jr. Renal atrophy and arterial stenosis: a prospective study with duplex ultrasound. Hypertension. 1994;23:346-350.
31. Caps MT, Zierler RE, Polissar NL, Bergelin RO, Beach KW, Cantwell-Gab K, Casadei A, Davidson RC, Strandness DE Jr. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int 1998;53:735-742.
32. Zierler RE, Bergelin RO, Isaacson JA, Strandness DE Jr. Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. J Vasc Surg. 1994;19:250-257.
33. Wright JR, Shurrab AE, Cheung C, Waldek S, O'Donoghue DJ, Foley RN, Mamtora H, Kalra PA. A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis. 2002;39:1153-1161.
34. Suresh M, Laboi P, Mamtora H, Kalra PA. Relationship of renal dysfunction to proximal arterial disease severity in atherosclerotic renovascular disease. Nephrol Dial Transplant. 2000;15:631-636.
35. Morgan T, Wilson M, Johnston W, Clunie GJ, Gordon R. Restoration of renal function by arterial surgery. Lancet. 1974;1:653-656.
36. Textor SC. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis. 1994;24:642-651.
37. Volpe M, Camargo MJ, Mueller FB, Campbell WG Jr, Sealey JE, Pecker MS, Sosa RE, Laragh JH. Relation of plasma renin to end organ damage and to protection of K+ feeding in stroke-prone hypertensive rats. Hypertension. 1990;15:318-326.
38. Teunissen KE, Postma CT, van Jaarsveld BC, Derkx FH, Thien T. Endothelin and active renin levels in essential hypertension and hypertension with renal artery stenosis before and after percutaneous transluminal renal angioplasty. J Hypertens. 1997;15:1791-1796.
39. Gobe GC, Axelsen RA, Searle JW. Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. Lab Invest. 1990;63:770-779.
40. Sheps SG, Osmundson PJ, Hunt JC, Schirger A, Fairbairn JF 2nd. Hypertension and renal artery stenosis: serial observations on 54 patients treated medically. Clin Pharmacol Ther. 1965;6:700-709.
41. Isles C, Main J, O'Connell J, Brown I, Findlay J, Stewart R, Wilkinson R. Survival associated with renovascular disease in Glasgow and Newcastle: a collaborative study. Scott Med J. 1990;35:70-73.
42. Valentine RJ, Myers SI, Miller GL, Lopez MA, Clagett GP. Detection of unsuspected renal artery stenoses in patients with abdominal aortic aneurysms: refined indications for preoperative aortography. Ann Vasc Surg. 1993;7:220-224.
43. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001;60:1490-1497.
44. Losito A, Fagugli RM, Zampi I, Parente B, de Rango P, Giordano G, Cao P. Comparison of target organ damage in renovascular and essential hypertension. Am J Hypertens. 1996;9:1062-1067.
45. de Simone G, Devereux RB, Volpe M, Camargo MJ, Wallerson DC, Laragh JH. Relation of left ventricular hypertrophy, afterload, and contractility to left ventricular performance in Goldblatt hypertension. Am J Hypertens. 1992;5:292-301.
46. Gavras H, Lever AF, Brown JJ, Macadam RF, Robertson JI. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet. 1971;2:19-22.
47. Yamazaki T, Shiojima I, Komuro I, Nagai R, Yazaki Y. Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction. J Hypertens. 1994;12:S153-S157.
48. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, Bauer C. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension. 1999;33:816-822.
49. Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension. 1992;19:25-32.
50. Robertson AL Jr, Khairallah PA. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science. 1971;172:1138-1139.
51. Ehmke H, Faulhaber J, Munter K, Kirchengast M, Wiesner RJ. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension. 1999;33:954-960.
52. Phillips PA. Interaction between endothelin and angiotensin II. Clin Exp Pharmacol Physiol. 1999;26:517-518.
53. Iwanaga Y, Kihara Y, Inagaki K, Onozawa Y, Yoneda T, Kataoka K, Sasayama S. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation. 2001;104:606-612.
54. Pessina AC, Sacchetto A, Rossi GP. Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension. Adv Exp Med Biol. 1997;432:63-69.
55. Silva JA, Chan AW, White CJ, Collins TJ, Jenkins JS, Reilly JP, Ramee SR. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation. 2005;111:328-333.
56. Broughton A, Korner PI. Left ventricular pump function in renal hypertensive dogs with cardiac hypertrophy. Am J Physiol. 1986;251:H1260-H1266.
57. Kannel WB. Role of blood pressure in cardiovascular disease: the Framingham study. Angiology. 1975;26:1-14.
58. Meissner MD, Wilson AR, Jessup M. Renal artery stenosis in heart failure. Am J Cardiol. 1988;62:1307-1308.
59. Olin JW. Atherosclerotic renovascular disease: diagnosis and management. Curr Opin Cardiol. 1990;5:659-665.
60. Khosla S, White CJ, Collins TJ, Jenkins JS, Shaw D, Ramee SR. Effects of renal artery stent implantation in patients with renovascular hypertension presenting with unstable angina or congestive heart failure. Am J Cardiol. 1997;80:363-366.
61. MacDowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet. 1998;352:13-16.
62. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
63. Sorensen MB, Bille Brahe NE. Preoperative haemodynamic evaluation of patients submitted for renal artery stenosis. Acta Anaesthesiol Scand. 1984;28:334-338.
64. MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, Crow R, Stamler J. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 1989;63:202-210.
65. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999;56:2214-2219.
66. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
67. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl. 1991;9:S3-S8.
68. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality: results from the Framingham study. Cardiology. 1992;81:291-298.
69. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate end-point in hypertension. Clin Exp Hypertens. 1999;21:583-593.
70. Sullivan JM, Vander Zwaag RV, el-Zeky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: effect on survival. J Am Coll Cardiol. 1993;22:508-513.
71. Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, Ruilope LM. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000;35:1038-1042.
72. Symonides B, Chodakowska J, Januszewicz A, Lapinski M, Januszewicz M, Rowinski O, Szmidt J, Kuch-Wocial A, Kurzyna M, Malek G, Berent H, Szmigielski C, Januszewicz W. Effects of the correction of renal artery stenosis on blood pressure, renal function and left ventricular morphology. Blood Press. 1999;8:141-150.
73. Missouris CG, Belli AM, MacGregor GA. "Apparent" heart failure: a syndrome caused by renal artery stenoses. Heart. 2000;83:152-155.
74. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113:e463-e654.
75. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
76. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
77. Dagenais GR, Yusuf S, Bourassa MG, Yi Q, Bosch J, Lonn EM, Kouz S, Grover J. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation. 2001;104:522-526.
78. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, Aurup P, Smith RD, Johansson M. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002;20:1855-1864.
79. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253:3263-3268.
80. MRC trial of treatment of mild hypertension: principal results: Medical Research Council Working Party. BMJ (Clin Res Ed). 1985;291:97-104.
81. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, McGlynn EA, Ware JE Jr. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA. 1989;262:907-913.
82. Oparil S, Calhoun DA. The calcium antagonists in the 1990s: an overview. Am J Hypertens. 1991;4:396S-405S.
83. Siegel D, Lopez J, Meier J, Cunningham F. Changes in the pharmacologic treatment of hypertension in the Department of Veterans Affairs 1997-1999: decreased use of calcium antagonists and increased use of beta-blockers and thiazide diuretics. Am J Hypertens. 2001;14:957-962.
84. Okano GJ, Rascati KL, Wilson JP, Remund DD. A comparison of antihypertensive medication utilization before and after guideline changes using the Department of Defense Prescription Database. Ann Pharmacother. 1999;33:548-553.
85. Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol. 1996;3:S125-S131.
86. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, Kiowski W, Fischli W. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219-227.
87. Hunt JC, Sheps SG, Harrison EG Jr, Strong CG, Bernatz PE. Renal and renovascular hypertension: a reasoned approach to diagnosis and management. Arch Intern Med. 1974;133:988-999.
88. Blum U, Krumme B, Flugel P, Gabelmann A, Lehnert T, Buitrago-Tellez C, Schollmeyer P, Langer M. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med. 1997;336:459-465.
89. Pizzolo F, Mansueto G, Minniti S, Mazzi M, Trabetti E, Girelli D, Corrocher R, Olivieri O. Renovascular disease: effect of ACE gene deletion polymorphism and endovascular revascularization. J Vasc Surg. 2004;39:140-147.
90. Rees CR, Palmaz JC, Becker GJ, Ehrman KO, Richter GM, Noeldge G, Katzen BT, Dake MD, Schwarten DE. Palmaz stent in atherosclerotic stenoses involving the ostia of the renal arteries: preliminary report of a multicenter study. Radiology. 1991;181:507-514.
91. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial: Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension. 1998;31:823-829.
92. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, Loose H, Main J, Padfield P, Russell IT, Walker B, Watson M, Wilkinson R. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis: Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens. 1998;12:329-335.
93. van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Man in 't Veld AJ, Schalekamp MA. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis: Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000;342:1007-1014.
94. Leertouwer TC, Gussenhoven EJ, Bosch JL, van Jaarsveld BC, van Dijk LC, Deinum J, Man In 't Veld AJ. Stent placement for renal arterial stenosis: where do we stand? A meta-analysis. Radiology. 2000;216:78-85.
95. Hennequin LM, Joffre FG, Rousseau HP, Aziza R, Tregant P, Bernadet P, Salvador M, Chamontin B. Renal artery stent placement: long-term results with the Wallstent endoprosthesis. Radiology. 1994;191:713-719.
96. Baumgartner I, von Aesch K, Do DD, Triller J, Birrer M, Mahler F. Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses: a prospective follow-up study. Radiology. 2000;216:498-505.
97. Kaatee R, Beek FJ, Verschuyl EJ, vd Ven PJ, Beutler JJ, van Schaik JP, Mali WP. Atherosclerotic renal artery stenosis: ostial or truncal? Radiology. 1996;199:637-640.
98. Burket MW, Cooper CJ, Kennedy DJ, Brewster PS, Ansel GM, Moore JA, Venkatesan J, Henrich WL. Renal artery angioplasty and stent placement: predictors of a favorable outcome. Am Heart J. 2000;139:64-71.
99. Harding MB, Smith LR, Himmelstein SI, Harrison K, Phillips HR, Schwab SJ, Hermiller JB, Davidson CJ, Bashore TM. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol. 1992;2:1608-1616.
100. Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galanski M, Koch KM, Haller H. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med. 2001;344:410-417.
101. Snow JB Jr, Kimmelman CP. Assessment of surgical procedures for Meniere's disease. Laryngoscope. 1979;89:737-747.
102. Chalmers TC, Matta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med. 1977;297:1091-1096.
103. Grace ND, Muench H, Chalmers TC. The present status of shunts for portal hypertension in cirrhosis. Gastroenterology. 1966;50:684-691.
104. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction: the Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321:406-412.
105. Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous renal artery interventions by Medicare beneficiaries, 1996-2000. AJR Am J Roentgenol. 2004;183:561-568.
106. Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, Burke GL, Dean RH. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002;36:443-451.